电子邮件 | nea***@***.com | 获取Email |
---|
电子邮件 | nea***@***.com | 获取Email |
---|
PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services. As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues. Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing. The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers. PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally. Why not get in touch to see how we can help you with your biosafety testing strategy?
公司 | PathoQuest |
---|---|
职位 | QA Specialist |
地点 | United States |
http://www.linkedin.com/in/neal-goldman-0333607 | |
部门 | master_engineering_technical,master_information_technology |
头衔 | Quality Assurance, Environmental Health and Safety, Clinical Research Management |
PathoQuest QA Specialist
2021-09-01 -
Rutgers University Center for Effective School Practices Biology Teaching Candidate enrolled with Rutgers-CESP
2020-08-01 - 2021-09-01
American CryoStem Corporation Quality Assurance-Regulatory Affairs Manager
2015-05-01 -
American CryoStem Corporation Regulatory Affairs Consultant
2013-05-01 - 2021-09-01
Bowling Green Clinical Associates, LLC President
2012-05-01 -
Neal Goldman 在 PathoQuest 担任 Quality Assurance, Environmental Health and Safety, Clinical Research Management
Neal Goldman 在 PathoQuest 的职位是 Quality Assurance, Environmental Health and Safety, Clinical Research Management
Neal Goldman 的电子邮件地址是 nea***@***.com
Neal Goldman 的电话号码是 -
Neal Goldman 的公司电话号码是 +331****
Neal Goldman 在 research 工作。
Neal Goldman 的一些同事包括Matt Chancler、Colette Cote、Chrystelle Stirnemann、Yoann LecatTristan Poisson、。
Neal Goldman联系方式: 电子邮件地址:nea***@***.com 电话号码:-
Neal Goldman 的个人领英是:http://www.linkedin.com/in/neal-goldman-0333607
Neal Goldman 的办公地点:11 rue Watt, Paris, Île-de-France, FR, 75013
Top-ranked on G2 Crowd
全球B2B企业库 海关贸易数据 展会采购数据
全球B2B企业库
海关贸易数据
展销采购数据
Top-ranked on G2 Crowd